Future role of topotecan in the treatment of lung cancer

Joan H. Schiller

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Topotecan (HYCAMTIN® GlaxoSmithKline, Brentford, Middlesex, UK) is a novel topoisomerase I inhibitor with potentially broad applicability in the treatment of solid and hematologic malignancies. In addition to its use in relapsed small-cell lung cancer (SCLC), topotecan is under investigation in numerous studies for first-line therapy in SCLC and for first- and second-line treatment of non-small-cell lung cancer (NSCLC). Preliminary evidence presented in this supplement demonstrates that single-agent topotecan and topotecan-based combination regimens are active in these settings. In addition to its potential use in SCLC and NSCLC, the feasibility and antitumor activity of topotecan as single-agent therapy and in combination therapy are under active investigation in a variety of other solid and hematologic tumors. Other important avenues of investigation include the feasibility and tumor activity of a more convenient oral formulation, as well as the investigation of alternate regimens (e.g., 3-day, weekly), with high priority given to regimen toxicity, patient convenience, and quality of life. Preliminary results of some of these trials are presented in this summary. The results of other clinical experience trials are eagerly anticipated.

Original languageEnglish (US)
Pages (from-to)55-59
Number of pages5
JournalOncology
Volume61
Issue numberSUPPL. 1
StatePublished - 2001

Fingerprint

Topotecan
Lung Neoplasms
Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
Topoisomerase I Inhibitors
Therapeutics
Hematologic Neoplasms
Neoplasms
Quality of Life
Clinical Trials

Keywords

  • Acute myelogenous leukemia
  • Myelodysplastic syndrome
  • Non-small-cell lung cancer
  • Oral formulation
  • Small-cell lung cancer
  • Topotecan

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Schiller, J. H. (2001). Future role of topotecan in the treatment of lung cancer. Oncology, 61(SUPPL. 1), 55-59.

Future role of topotecan in the treatment of lung cancer. / Schiller, Joan H.

In: Oncology, Vol. 61, No. SUPPL. 1, 2001, p. 55-59.

Research output: Contribution to journalArticle

Schiller, JH 2001, 'Future role of topotecan in the treatment of lung cancer', Oncology, vol. 61, no. SUPPL. 1, pp. 55-59.
Schiller, Joan H. / Future role of topotecan in the treatment of lung cancer. In: Oncology. 2001 ; Vol. 61, No. SUPPL. 1. pp. 55-59.
@article{e4a1fbf154824926859892b1f349a8e6,
title = "Future role of topotecan in the treatment of lung cancer",
abstract = "Topotecan (HYCAMTIN{\circledR} GlaxoSmithKline, Brentford, Middlesex, UK) is a novel topoisomerase I inhibitor with potentially broad applicability in the treatment of solid and hematologic malignancies. In addition to its use in relapsed small-cell lung cancer (SCLC), topotecan is under investigation in numerous studies for first-line therapy in SCLC and for first- and second-line treatment of non-small-cell lung cancer (NSCLC). Preliminary evidence presented in this supplement demonstrates that single-agent topotecan and topotecan-based combination regimens are active in these settings. In addition to its potential use in SCLC and NSCLC, the feasibility and antitumor activity of topotecan as single-agent therapy and in combination therapy are under active investigation in a variety of other solid and hematologic tumors. Other important avenues of investigation include the feasibility and tumor activity of a more convenient oral formulation, as well as the investigation of alternate regimens (e.g., 3-day, weekly), with high priority given to regimen toxicity, patient convenience, and quality of life. Preliminary results of some of these trials are presented in this summary. The results of other clinical experience trials are eagerly anticipated.",
keywords = "Acute myelogenous leukemia, Myelodysplastic syndrome, Non-small-cell lung cancer, Oral formulation, Small-cell lung cancer, Topotecan",
author = "Schiller, {Joan H.}",
year = "2001",
language = "English (US)",
volume = "61",
pages = "55--59",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Future role of topotecan in the treatment of lung cancer

AU - Schiller, Joan H.

PY - 2001

Y1 - 2001

N2 - Topotecan (HYCAMTIN® GlaxoSmithKline, Brentford, Middlesex, UK) is a novel topoisomerase I inhibitor with potentially broad applicability in the treatment of solid and hematologic malignancies. In addition to its use in relapsed small-cell lung cancer (SCLC), topotecan is under investigation in numerous studies for first-line therapy in SCLC and for first- and second-line treatment of non-small-cell lung cancer (NSCLC). Preliminary evidence presented in this supplement demonstrates that single-agent topotecan and topotecan-based combination regimens are active in these settings. In addition to its potential use in SCLC and NSCLC, the feasibility and antitumor activity of topotecan as single-agent therapy and in combination therapy are under active investigation in a variety of other solid and hematologic tumors. Other important avenues of investigation include the feasibility and tumor activity of a more convenient oral formulation, as well as the investigation of alternate regimens (e.g., 3-day, weekly), with high priority given to regimen toxicity, patient convenience, and quality of life. Preliminary results of some of these trials are presented in this summary. The results of other clinical experience trials are eagerly anticipated.

AB - Topotecan (HYCAMTIN® GlaxoSmithKline, Brentford, Middlesex, UK) is a novel topoisomerase I inhibitor with potentially broad applicability in the treatment of solid and hematologic malignancies. In addition to its use in relapsed small-cell lung cancer (SCLC), topotecan is under investigation in numerous studies for first-line therapy in SCLC and for first- and second-line treatment of non-small-cell lung cancer (NSCLC). Preliminary evidence presented in this supplement demonstrates that single-agent topotecan and topotecan-based combination regimens are active in these settings. In addition to its potential use in SCLC and NSCLC, the feasibility and antitumor activity of topotecan as single-agent therapy and in combination therapy are under active investigation in a variety of other solid and hematologic tumors. Other important avenues of investigation include the feasibility and tumor activity of a more convenient oral formulation, as well as the investigation of alternate regimens (e.g., 3-day, weekly), with high priority given to regimen toxicity, patient convenience, and quality of life. Preliminary results of some of these trials are presented in this summary. The results of other clinical experience trials are eagerly anticipated.

KW - Acute myelogenous leukemia

KW - Myelodysplastic syndrome

KW - Non-small-cell lung cancer

KW - Oral formulation

KW - Small-cell lung cancer

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=0035742140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035742140&partnerID=8YFLogxK

M3 - Article

C2 - 11598416

AN - SCOPUS:0035742140

VL - 61

SP - 55

EP - 59

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - SUPPL. 1

ER -